205 related articles for article (PubMed ID: 16160620)
1. Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness.
de Leon J; Susce MT; Pan RM; Koch WH; Wedlund PJ
J Clin Psychopharmacol; 2005 Oct; 25(5):448-56. PubMed ID: 16160620
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism.
Lerer B; Segman RH; Fangerau H; Daly AK; Basile VS; Cavallaro R; Aschauer HN; McCreadie RG; Ohlraun S; Ferrier N; Masellis M; Verga M; Scharfetter J; Rietschel M; Lovlie R; Levy UH; Meltzer HY; Kennedy JL; Steen VM; Macciardi F
Neuropsychopharmacology; 2002 Jul; 27(1):105-19. PubMed ID: 12062911
[TBL] [Abstract][Full Text] [Related]
3. Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European-Brazilian schizophrenics.
Kohlrausch FB; Gama CS; Lobato MI; Belmonte-de-Abreu P; Callegari-Jacques SM; Gesteira A; Barros F; Carracedo A; Hutz MH
Pharmacogenet Genomics; 2008 Jul; 18(7):599-609. PubMed ID: 18551040
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacogenetic assessment of antipsychotic-induced tardive dyskinesia: contribution of 5-hydroxytryptamine 2C receptor gene and of a combination of dopamine D3 variant allele (Gly) and MnSOD wild allele (Val)].
Zhang Z; Hou G; Zhang X; Yao H; Sha W; Zhang X
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Apr; 20(2):98-102. PubMed ID: 12673575
[TBL] [Abstract][Full Text] [Related]
5. Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients.
Fu Y; Fan CH; Deng HH; Hu SH; Lv DP; Li LH; Wang JJ; Lu XQ
Acta Pharmacol Sin; 2006 Mar; 27(3):328-32. PubMed ID: 16490169
[TBL] [Abstract][Full Text] [Related]
6. CYP2D6 polymorphism and tardive dyskinesia in schizophrenic patients.
Lohmann PL; Bagli M; Krauss H; Müller DJ; Schulze TG; Fangerau H; Ludwig M; Barkow K; Held T; Heun R; Maier W; Rietschel M; Rao ML
Pharmacopsychiatry; 2003; 36(2):73-8. PubMed ID: 12734765
[TBL] [Abstract][Full Text] [Related]
7. Association analysis of the dopamine D3 receptor gene ser9gly and brain-derived neurotrophic factor gene val66met polymorphisms with antipsychotic-induced persistent tardive dyskinesia and clinical expression in Chinese schizophrenic patients.
Liou YJ; Liao DL; Chen JY; Wang YC; Lin CC; Bai YM; Yu SC; Lin MW; Lai IC
Neuromolecular Med; 2004; 5(3):243-51. PubMed ID: 15626824
[TBL] [Abstract][Full Text] [Related]
8. ABCB1, ABCG2 and CYP2D6 polymorphism effects on disposition and response to long-acting risperidone.
Ganoci L; Trkulja V; Živković M; Božina T; Šagud M; Lovrić M; Božina N
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jan; 104():110042. PubMed ID: 32682874
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms of dopamine receptors and tardive dyskinesia among Chinese patients with schizophrenia.
Chong SA; Tan EC; Tan CH; Mythily ; Chan YH
Am J Med Genet B Neuropsychiatr Genet; 2003 Jan; 116B(1):51-4. PubMed ID: 12497614
[TBL] [Abstract][Full Text] [Related]
10. Effects of CYP2D6, CYP3A5, and ABCB1 gene polymorphisms on the pharmacokinetics of two risperidone long-acting injection microsphere formulations.
Ma L; Xiang Q; Zhao N; Hu C; Fang M; Tan Y; Chen S; Wang Z; Liu P; Sun K; Li Y; Wu F; Tian H; Fang M; Zhao X; Wang G; Cui Y
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jul; 109():110241. PubMed ID: 33400943
[TBL] [Abstract][Full Text] [Related]
11. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms.
Tiwari AK; Deshpande SN; Rao AR; Bhatia T; Lerer B; Nimgaonkar VL; Thelma BK
Schizophr Res; 2005 Jun; 75(1):21-6. PubMed ID: 15820320
[TBL] [Abstract][Full Text] [Related]
12. Influence of genetic polymorphisms in CYP3A4, CYP3A5, GSTP1, GSTM1, GSTT1 and MDR1 genes on survival and therapy-related toxicity in multiple myeloma.
Schilthuizen C; Broyl A; van der Holt B; de Knegt Y; Lokhorst H; Sonneveld P
Haematologica; 2007 Feb; 92(2):277-8. PubMed ID: 17296590
[TBL] [Abstract][Full Text] [Related]
13. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation.
de Leon J; Susce MT; Pan RM; Fairchild M; Koch WH; Wedlund PJ
J Clin Psychiatry; 2005 Jan; 66(1):15-27. PubMed ID: 15669884
[TBL] [Abstract][Full Text] [Related]
14. Association of tardive dyskinesia with variation in CYP2D6: Is there a role for active metabolites?
Koola MM; Tsapakis EM; Wright P; Smith S; Kerwin Rip RW; Nugent KL; Aitchison KJ
J Psychopharmacol; 2014 Jul; 28(7):665-70. PubMed ID: 24595968
[TBL] [Abstract][Full Text] [Related]
15. Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients.
Liou YJ; Wang YC; Bai YM; Lin CC; Yu SC; Liao DL; Lin MW; Chen JY; Lai IC
Neuropsychobiology; 2004; 49(4):167-73. PubMed ID: 15118351
[TBL] [Abstract][Full Text] [Related]
16. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients.
Steen VM; Løvlie R; MacEwan T; McCreadie RG
Mol Psychiatry; 1997 Mar; 2(2):139-45. PubMed ID: 9106238
[TBL] [Abstract][Full Text] [Related]
17. Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety.
Xiang Q; Zhao X; Zhou Y; Duan JL; Cui YM
J Clin Pharmacol; 2010 Jun; 50(6):659-66. PubMed ID: 20332423
[TBL] [Abstract][Full Text] [Related]
18. Association between three functional polymorphisms of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia.
Hori H; Ohmori O; Shinkai T; Kojima H; Nakamura J
Am J Med Genet; 2001 Dec; 105(8):774-8. PubMed ID: 11803529
[TBL] [Abstract][Full Text] [Related]
19. Cytochrome P450 2D6 and glutathione S-transferase genotype in sudden infant death syndrome.
Chen CL; Liu Q; Evans WE; Sander CH; Relling MV
J Paediatr Child Health; 1997 Feb; 33(1):31-7. PubMed ID: 9069041
[TBL] [Abstract][Full Text] [Related]
20. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
Plesnicar BK; Zalar B; Breskvar K; Dolzan V
J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]